New Label-Free Biosensing for the Evaluation of the AX-024 Inhibitor: Case Study for the Development of New Drugs in Autoimmune Diseases

We developed a new label-free assay to evaluate the inhibition capacity of AX-024 by means of a new Point-of-Care (PoC) device for application in the development of new drugs in autoimmune diseases. The technology of PoC is based on interferometric optical detection method (IODM). For this purpose,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramírez, Yolanda, Laguna, María Fe, Holgado, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8839007/
https://www.ncbi.nlm.nih.gov/pubmed/35161965
http://dx.doi.org/10.3390/s22031218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8839007/
https://www.ncbi.nlm.nih.gov/pubmed/35161965
http://dx.doi.org/10.3390/s22031218

Ejemplares similares